Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune Thrombocytopenia

NCT06291415 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT06291415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06291415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune Thrombocytopenia
Lead sponsor
Hutchmed
Phase
Phase 1
Overall status
Withdrawn
Start date
April 2, 2024
Completion date
November 30, 2026
Enrollment
0 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, blood coagulation disorder, blood platelet disorder, hematologic diseases, hemorrhage, hemorrhagic disorders, immune system diseases, immune thrombocytopenia, itp - immune thrombocytopenia, pathologic processes, primary immune thrombocytopenia, purpura, purpura, thrombocytopenic, purpura, thrombocytopenic, idiopathic, skin manifestations, thrombocytopenia, thrombotic microangiopathies